Praxis Precision

$17.15 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Praxis Precision

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.

Stock Analysis

last close $17.15
1-mo return -21.1%
3-mo return -12.9%
avg daily vol. 233.62T
52-week high 60.95
52-week low 12.71
market cap. $752M
forward pe -
annual div. -
roe -155.4%
ltg forecast 13.3%
dividend yield -
annual rev. $--
inst own. 97%
baraka

Subscribe now for daily local and international financial news

Subscribe